<DOC>
	<DOCNO>NCT01316874</DOCNO>
	<brief_summary>This Phase II/Phase III study intravesical AD 32 ( valrubicin ) patient carcinoma situ ( CIS ) previously treat intravesical Bacillus Calmette-Guerin ( BCG ) CIS recurrence failure occur multiple course intravesical treatment .</brief_summary>
	<brief_title>Intravesical AD 32 ( Valrubicin ) Patients With Carcinoma Situ ( CIS ) Bladder Who Have Failed Have Recurrence Following Treatment With Bacillus Calmette-guerin ( BCG )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<mesh_term>Valrubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Inclusion 1 . Patients must pathologicallyproven CIS evidence muscle invasive disease . 2 . Patients concurrent Ta T1 papillary tumor eligible provide papillary tumor ( ) resect prior study treatment . Cystoscopic evaluation , indicate , transurethral resection bladder tumor ( TURBT ) must perform within 28 day study treatment . 3 . Patients must receive least two prior course intravesical therapy CIS per recommend schedule . BCG must one prior therapy administer . Patients either fail BCG therapy successfully treat BCG , subsequently find recurrence . The standard course intravesical therapy must include six weekly treatment ( allowable range instillation per course 49 ) . 4 . Patients must positive urine cytology baseline ( &lt; 28 day ) prior first AD 32 ( valrubicin ) treatment . Patients papillary lesion must positive cytology follow TURBT baseline cytology negative equivocal histologic confirmation CIS . 5 . Patients must ECOG performance status 02 life expectancy least 6 month . Exclusion 1 . Patients urogenital tumor histology transitional cell carcinoma 2 . Patients residual papillary disease time study treatment . 3 . Patients history primary malignancy ( squamous basal cell skin cancer ) within last 5 year . 4 . Patients evidence muscle invasive disease ( stage high T1 ) . 5 . Patients previous intravesical treatment AD 32 ( valrubicin ) . 6 . Patients intravesical therapy within 28 day prior first AD 32 ( valrubicin ) treatment . 7 . Patients plan receive concurrent therapy treatment primary treatment tumor participation study . 8 . Patients receive prior systemic radiation therapy bladder cancer . 9 . Women pregnant lactating . Individuals reproductive potential could participate unless agree use effective contraceptive method and/or sexual partner . 10 . Patients , investigator 's opinion , could comply provision protocol understand nature study . 11 . Patients , opinion investigator , could tolerate intravesical administration approximately 75 mL fluid could tolerate surgical manipulation ( cystoscopy , map biopsy , barbotage ) due presence concomitant serious illness ( ie , uncontrolled cardiac respiratory disorder ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Valrubicin</keyword>
	<keyword>CIS</keyword>
	<keyword>AD 32 , BCG-refractory CIS</keyword>
	<keyword>Carcinoma situ ( CIS ) previously treat BCG</keyword>
</DOC>